10-K: American Vanguard Reports Significant 2024 Net Loss Amidst Major Transformation and Asset Impairments

American Vanguard Corporation announced a substantial net loss of $126.3 million for 2024, driven by significant nonrecurring charges and a decline in sales, as the company undergoes a major business and digital transformation under new leadership.

Summary

• American Vanguard Corporation (AVD) reported a net loss of $126,340 thousand ($4.50 per share) for the year ended December 31, 2024, a significant decline from a net income of $7,519 thousand ($0.26 per share) in 2023.
• The loss was primarily due to $117,355 thousand in nonrecurring charges, including business transformation expenses, impairment of SIMPAS precision application technology, Dacthal herbicide cancellation costs, goodwill and intangible asset impairments, and inventory write-downs.
• Net sales decreased by 6% to $547,306 thousand in 2024 from $579,371 thousand in 2023, with U.S. crop sales down 15% and international sales up 1%.
• Gross margin dropped to 22% in 2024 from 31% in 2023, attributed to elevated raw material prices, Dacthal recall costs ($12,200 thousand in customer credits, $3,153 thousand in inventory write-downs), and $21,417 thousand in additional inventory write-downs for obsolete items.
• Operating expenses increased by 42% to $221,872 thousand in 2024, largely due to the non-cash asset impairment charges and digital/structural transformation strategy costs.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2024, related to control environment, control activities, risk assessment, and review of customer agreements.
• Douglas A. Kaye III was recruited and hired as the new CEO in mid-December 2024 to lead the company's transformation efforts.
• Cash dividends and share repurchases have been suspended since November 7, 2023, due to amendments to the senior credit facility agreement.
• The company's average indebtedness increased to $195,160 thousand in 2024 from $167,976 thousand in 2023, leading to higher interest expense.
• The effective tax rate for 2024 was negative 4.9%, primarily due to the establishment of a valuation allowance against U.S. net deferred tax assets.

Sentiment

Score: 3

Explanation: The company reported a substantial net loss, significant asset impairments, and identified material weaknesses in internal controls, indicating severe financial underperformance. While strategic transformation efforts and new leadership are in place, the immediate financial results are very poor, and the suspension of dividends and share repurchases signals financial strain. The overall outlook is challenging despite long-term strategic goals.

Positives

• The company initiated decisive business and digital transformation initiatives aimed at achieving stronger growth, profitability, and improved operating leverage.
• A new CEO, Douglas A. Kaye III, with extensive crop protection industry experience, was hired in mid-December 2024 to expedite transformation efforts.
• The U.S. non-crop business segment showed improvement, with sales increasing by 9% compared to the previous year.
• International sales increased by 1%, with granular soil insecticides, the largest international product category, exhibiting strength with a 10% increase.
• The company's investments in biofertilizers, biostimulants, and biochemicals are showing growth, outpacing the broader agricultural economy.
• Net sales improved in the fourth quarter of 2024, and customer prepayment activity helped reduce inventory and indebtedness by year-end.
• Management is committed to addressing and remediating the identified material weaknesses in internal control over financial reporting, with remediation measures already underway.

Negatives

• Reported a significant net loss of $126,340 thousand in 2024, a substantial reversal from net income in prior years.
• Incurred $117,355 thousand in total nonrecurring charges, including business transformation expenses, asset impairments, and inventory write-downs.
• Overall net sales declined by 6% in 2024, with U.S. crop business sales down 15%.
• Experienced a 40% drop in sales of the high-margin granular insecticide Aztec due to customer destocking.
• Voluntarily cancelled and recalled the Dacthal herbicide product, resulting in $12,200 thousand in customer credits and $3,153 thousand in inventory write-downs and disposal costs.
• Gross margin significantly decreased to 22% in 2024 from 31% in 2023.
• Cost of sales increased by 7% to 78% of net sales, impacted by elevated raw material prices and inventory write-downs.
• Operating expenses rose by 42% in 2024, primarily due to non-cash asset impairment charges and transformation costs.
• Recorded goodwill impairment charges of $27,049 thousand and intangible asset impairment charges of $9,345 thousand.
• Average indebtedness increased to $195,160 thousand in 2024, leading to higher interest expense.
• Suspended cash dividends and share repurchases effective November 7, 2023, due to credit facility amendments.
• Identified material weaknesses in internal control over financial reporting, indicating a reasonable possibility of material misstatements not being prevented or detected timely.
• Experienced a negative foreign currency translation adjustment of $12,766 thousand in 2024.
• Increased valuation allowance against deferred tax assets by $29,730 thousand in 2024.

Risks

• Compliance with environmental and other regulations or changes in them could increase costs or limit the ability to market products, especially in regions like the EU with hazard-based analysis.
• Inability to obtain or maintain pesticide registrations, or cancellation of existing ones (e.g., PCNB proposed cancellation), could adversely affect business.
• Public statements by the USEPA regarding products like DCPA (Dacthal) could expose the company to future personal injury claims and make product liability insurance difficult to obtain.
• Petitions to revoke tolerances for organophosphate products could lead to limitations or cancellations of registrations, materially affecting financial performance.
• Product liability judgments against other companies in the industry (e.g., glyphosate cases) could set precedents, leading to similar lawsuits against the company.
• State-level pesticide ban-bills could target the company's registered products, adversely affecting financial performance.
• Continuing challenges from activist groups under various federal, state, and foreign statutes could succeed, resulting in adverse effects on financial performance.
• Dependence on sole or limited suppliers for certain raw materials and active ingredients poses a risk to supply continuity and projected sales.
• Disruptions in the global supply chain, including sourcing outside the U.S., tariffs, and international trade wars, could increase costs or cause supply disruptions.
• Fluctuations and volatility in the global economy, including inflation, foreign currency exchange rates, and interest rates, could negatively impact results of operations.
• Climate change may adversely affect the company's business by reducing demand for products due to inconsistent weather conditions or disrupting operations.
• Demand for products varies with weather conditions and commodity prices, which could reduce revenues and profitability.
• The company may be subject to environmental liabilities, including fines and penalties for violations or accidental contamination.
• The highly competitive nature of markets, increased generic presence, and industry consolidation could adversely affect the company's ability to maintain or grow revenues.
• Identified material weaknesses in internal control over financial reporting could adversely affect financial reporting accuracy, stock price, and investor confidence.
• The company's transformation initiatives may not generate the full targeted efficiencies or a sufficient return on investment.
• Reduced financial performance may limit the company's ability to borrow under its credit facility, impacting future acquisitions or working capital needs.
• Dependence on customer prepayments to meet working capital needs poses a risk if customers reduce participation in the program.
• The carrying value of certain assets (long-lived assets, inventory, fixed assets, intangibles) may be subject to future impairment depending on market trends and other factors.
• The company's computing systems are subject to cybersecurity risks, including hacking, phishing, and data compromise, which could affect operations and reputation.
• Failure to fully realize capacity utilization at manufacturing facilities could lead to lower profitability.
• Domestic and regional inflation trends, increased interest rates, and potential recessionary periods could adversely impact the company's financial performance.
• Newly acquired businesses or product lines may not generate forecasted results, leading to adverse financial effects.
• Investments in foreign businesses may pose additional risks due to political, economic, or currency instability.
• Investments in technology may not generate forecasted returns or gain commercial acceptance.
• The company's growth, historically fueled by acquisitions, may be hindered if suitable acquisition targets or licensing opportunities are not available or affordable.
• Competition from generic competitors with lower cost structures could drive down pricing and profitability.
• Industry consolidation among competitors could make it more difficult for the company to compete in various markets.
• The company's customer base is relatively concentrated, with the top three customers accounting for 38% of sales in 2024, exposing it to risks from changes in their purchasing behavior or financial instability.

Future Outlook

The company expects a gradual recovery from 2024, with biofertilizers, biostimulants, and biochemicals anticipated to grow faster than the broader agricultural economy. Management is focused on realizing substantial benefits from the ongoing business and digital transformation initiatives, aiming for greater operational efficiency, growth, and beneficial change, and expects to proceed into 2025 with an improved balance sheet and strong, focused leadership.

Management Comments

• "AVD took decisive and necessary measures to transform its entire enterprise into a platform for stronger growth and profitability."
• "The Company is moving with speed and intention to realize the substantial benefits of transformation and to return greater value to shareholders, as the new CEO leads the Company toward greater operational efficiency, growth and beneficial change."
• "The vast majority of business transformation expenses were incurred in 2024. In subsequent years, the Company will be advancing the implementation plan largely through internal resources."
• "The Company proceeds into 2025 with an improved balance sheet and strong, focused leadership for realizing the benefits from our transformation efforts."
• "Most of the underperformance in sales was driven by two factors a 40% drop in sales of the granular insecticide Aztec following unusually high sales in the prior year as a result of a period of product unavailability, and the impact of the voluntary cancellation and recall of the herbicide Dacthal."
• "Supply chains are beginning to normalize, but given the current economic backdrop it may be some time before consumers are inclined to meaningfully increase their inventory levels."
• "Some pockets of strength are present, with biofertilizers, biostimulants and biochemicals growing much faster than the broader agricultural economy."
• "The Company believes that the combination of its cash flows from future operations, current cash on hand and the availability under the Companys credit facility will be sufficient to meet its working capital and capital expenditure requirements and will provide the Company with adequate liquidity to meet its anticipated operating needs for at least the next 12 months from the issuance of these consolidated financial statements."
• "The Company believes that, overall, executive compensation for 2024 was consistent with the rubric of pay-for-performance."

Industry Context

The agricultural chemical industry is cyclical, with demand for products influenced by weather conditions, pest pressure, and commodity prices of crops. The global agriculture market is currently experiencing a trend where customers prefer to buy smaller quantities closer to the time of use, relying on suppliers to hold inventory, driven by high interest rates. The industry is also undergoing significant consolidation, leading to larger competitors with greater economies of scale and market reach. There is an increasing presence of generic products, and new technologies like precision pest prediction and data management are emerging, which could disrupt the business.

Comparison to Industry Standards

• The company's one-year, three-year, and five-year Total Shareholder Return (TSR) was below the 25th percentile of its Proxy Peers, which include AdvanSix Inc., Arcadium Lithium plc, Aspen Aerogels, Inc., Balchem Corporation, Core Molding Technologies, Inc., CVR Partners LP, Ecovyst Inc., Hawkins, Inc., Haynes International, Inc., Innospec Inc., Intrepid Potash, Inc., LSB Industries, Inc., Quaker Chemical Corporation, and Tredegar Corporation.
• American Vanguard is noted as the only publicly traded crop protection company of its size, and none of the identified Proxy Peers operate in the crop protection sector, indicating a lack of direct comparable public companies.
• The CEO's base salary was below the 25th percentile of the Proxy Peers.
• The CEO's bonus amount ($0) for 2024 was below the 25th percentile for target bonus of the Proxy Peers.
• The annualized total cash compensation for the CEO was below the 25th percentile for target total cash of the Proxy Peers.
• Equity granted in 2024 to the CEO was between the 25th percentile and the median of the Proxy Peers.
• The annualized total direct compensation for the company's CEO was below the 25th percentile of the Proxy Peers.
• On average, compensation for other Named Executive Officers (NEOs) showed salaries at approximately the 25th percentile, while incentive cash, total cash (excluding nonrecurring transformation benefit), equity, and total direct compensation were below the 25th percentile for the Proxy Peers.

Management Changes

Corporate Governance

Legal Proceedings

• **Department of Justice and Environmental Protection Agency Investigation**: The company pleaded guilty to one count of transporting hazardous waste without a waste manifest (related to reimportation of used containers in 2014), paid a fine, and entered a three-year probation subject to an environmental compliance plan.
• **DBCP Cases (Chavez & Marquinez)**: Ongoing lawsuits in U.S. District Court for the District of Delaware involving claims from approximately 290 banana workers for personal injury allegedly arising from DBCP exposure; trials for Ecuadorian plaintiffs are set to begin in February 2026. The company does not believe a loss is probable or reasonably estimable at this stage.
• **Pitre etc. v. Agrocentre Ladauniere et al.**: A strawberry grower filed a complaint in Quebec, Canada, seeking approximately $5 million in damages for stunted growth and reduced yield allegedly from Vapam soil fumigant application; the company believes the claims have no merit as the plaintiff did not follow product label directions.
• **Catalano v. AMVAC Chemical Corp.**: A lawsuit in California Superior Court where a professional pesticide applicator seeks damages for cardiomyopathy allegedly from Orthene exposure; the company is unaware of any link between the product and the alleged condition and believes the case has no merit.
• **Reyes v. AMVAC**: A class action lawsuit alleging wage and hour violations under California law; the parties have agreed in principle to a settlement, and a reserve has been recorded (not material), with court approval expected in Q3 2025.
• **Region 9, Notice of Violation re: FPAS**: EPA Region IX issued a letter alleging that AMVAC exported 18 unregistered pesticides to 14 countries without submitting Foreign Purchaser Acknowledgement Statements (FPAS) from 2020-2023; the company is performing internal analysis and has set a non-material reserve, with resolution extended to June 2025 via a tolling agreement.

Related Party Transactions

• Company director Mark Bassett entered into a consulting arrangement from January to March 2024, receiving approximately $95,200 for operational and business analytics services.
• Mr. Bassett resumed his consultancy in July 2024 in support of the Office of CEO (OCEO), receiving a flat rate of $29,200 per month and a transformation benefit of $125,000 for each of the third and fourth quarters of 2024.

Stakeholder Impact

• **Shareholders**: Experienced a significant net loss in 2024, suspension of cash dividends and share repurchases, and underperformance in Total Shareholder Return (TSR) compared to industry peers. The company's transformation efforts aim to return greater value to shareholders in the future.
• **Employees**: Received a modest bonus in 2024 as recognition for their support during a challenging transformation year. The company continues to offer competitive compensation and comprehensive benefits, including a 401K retirement savings plan and an Employee Stock Purchase Plan. Employee count decreased from 845 in 2023 to 755 in 2024.
• **Customers**: Impacted by the voluntary cancellation and recall of Dacthal, resulting in customer credits. Customers are currently preferring smaller, more frequent orders, shifting inventory holding responsibility to suppliers.
• **Suppliers**: The company is actively engaging with critical raw material suppliers to manage inflationary pressures and tariff impacts, indicating ongoing relationships and negotiations.
• **Creditors**: The company's financial performance led to increased average indebtedness and required multiple amendments to its senior credit facility to maintain compliance with financial covenants. New covenants related to minimum liquidity and EBITDA targets have been introduced, indicating closer monitoring by lenders.

Next Steps

• Advance the implementation plan for business transformation, primarily utilizing internal resources in subsequent years.
• Remediate identified material weaknesses in internal control over financial reporting by enhancing oversight, adding resources, improving risk assessment, and refining review processes for customer agreements.
• Continue to search for a partner to fund large-scale commercialization of the SIMPAS technology.
• Defend product registrations against ongoing regulatory challenges, particularly concerning organophosphates (OPs) and PCNB.
• Manage the effects of inflation and high interest rates to mitigate their impact on financial performance.
• Attain minimum year-to-date Consolidated EBITDA targets: $4,500 thousand by June 30, 2025; $9,500 thousand by September 30, 2025; and $35,000 thousand by December 31, 2025.
• Maintain minimum monthly liquidity targets ranging from $30,000 thousand to $3,000 thousand from June 30, 2025, through December 31, 2025.
• Await court approval for the Reyes v. AMVAC settlement, expected during Q3 2025.
• Address the EPA Notice of Violation regarding Foreign Purchaser Acknowledgement Statements (FPAS), with the tolling agreement extending resolution to June 2025.
• Prepare for the first trials in the Chavez & Marquinez DBCP cases, set to begin in February 2026.
• The Board intends to segregate the roles of Chair and CEO in the future.

Key Dates

Recommendation

Keywords

American Vanguard, AVD, SEC filing, 10-K, crop protection, agricultural chemicals, pesticides, insecticides, fungicides, herbicides, financial results, net loss, asset impairment, goodwill impairment, internal controls, corporate governance, supply chain, regulatory risk, Dacthal, SIMPAS, debt, liquidity, business transformation, inventory write-down, environmental compliance, executive compensation